EA201391012A1 - Лиганды, связывающиеся с рецепторами tgf-бета типа ii - Google Patents
Лиганды, связывающиеся с рецепторами tgf-бета типа iiInfo
- Publication number
- EA201391012A1 EA201391012A1 EA201391012A EA201391012A EA201391012A1 EA 201391012 A1 EA201391012 A1 EA 201391012A1 EA 201391012 A EA201391012 A EA 201391012A EA 201391012 A EA201391012 A EA 201391012A EA 201391012 A1 EA201391012 A1 EA 201391012A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- fibrosis
- tgfβrii
- amino acid
- variable domain
- accordingly
- Prior art date
Links
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 title 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 abstract 4
- 230000004761 fibrosis Effects 0.000 abstract 3
- 108060003951 Immunoglobulin Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000018358 immunoglobulin Human genes 0.000 abstract 2
- 206010008909 Chronic Hepatitis Diseases 0.000 abstract 1
- 208000001708 Dupuytren contracture Diseases 0.000 abstract 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 208000002260 Keloid Diseases 0.000 abstract 1
- 206010023330 Keloid scar Diseases 0.000 abstract 1
- 206010023421 Kidney fibrosis Diseases 0.000 abstract 1
- 206010050207 Skin fibrosis Diseases 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 210000001117 keloid Anatomy 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 201000009925 nephrosclerosis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000037390 scarring Effects 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161430235P | 2011-01-06 | 2011-01-06 | |
| PCT/EP2012/050061 WO2012093125A1 (en) | 2011-01-06 | 2012-01-04 | Ligands that bind tgf-beta receptor ii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201391012A1 true EA201391012A1 (ru) | 2014-01-30 |
Family
ID=45444622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201391012A EA201391012A1 (ru) | 2011-01-06 | 2012-01-04 | Лиганды, связывающиеся с рецепторами tgf-бета типа ii |
Country Status (22)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| CN103443126B (zh) * | 2011-01-06 | 2016-11-23 | 葛兰素集团有限公司 | 结合TGFβ受体II的配体 |
| SG194982A1 (en) * | 2011-06-23 | 2013-12-30 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| KR102233349B1 (ko) * | 2013-03-15 | 2021-03-31 | 에이씨 이뮨 에스.에이. | 항-타우(tau) 항체 및 사용 방법 |
| CN105164157B (zh) | 2013-04-29 | 2024-05-28 | 豪夫迈·罗氏有限公司 | Fc-受体结合的修饰的非对称抗体及使用方法 |
| HK1225742A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma, Inc. | TGF-β受体II型变体及其用途 |
| CA2931309C (en) * | 2013-11-21 | 2022-06-21 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating pulmonary hypertension |
| CN110981957B (zh) | 2014-01-15 | 2024-12-24 | 豪夫迈·罗氏有限公司 | 具有改善的蛋白A结合作用的Fc区变体 |
| EP3094649A1 (en) * | 2014-01-15 | 2016-11-23 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn-binding properties |
| EP3174550B1 (en) * | 2014-08-01 | 2020-01-29 | The Brigham and Women's Hospital, Inc. | Methods and compositions relating to treatment of pulmonary arterial hypertension |
| MY193078A (en) | 2015-06-24 | 2022-09-26 | Hoffmann La Roche | Anti-transferrin receptor antibodies with tailored affinity |
| CN108348578B (zh) | 2015-08-04 | 2022-08-09 | 阿塞勒隆制药公司 | 用于治疗骨髓增生性病症的方法 |
| WO2017041114A2 (en) * | 2015-09-03 | 2017-03-09 | The Children's Mercy Hospital | Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof |
| CN108137697A (zh) | 2015-10-02 | 2018-06-08 | 豪夫迈·罗氏有限公司 | 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法 |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| PL3374392T3 (pl) * | 2015-11-13 | 2022-03-28 | Ablynx Nv | Ulepszone domeny zmienne immunoglobuliny wiążące albuminę surowicy |
| KR20180131557A (ko) * | 2016-04-05 | 2018-12-10 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 면역요법에서의 tgf베타의 억제 |
| RS64315B1 (sr) | 2017-05-04 | 2023-08-31 | Acceleron Pharma Inc | Fuzioni proteini tgf-beta receptora tipa ii i njihove upotrebe |
| GB201807693D0 (en) * | 2018-05-11 | 2018-06-27 | Autolus Ltd | Cell |
| WO2020009248A1 (ja) * | 2018-07-04 | 2020-01-09 | 京都府公立大学法人 | 眼組織の線維化抑制用組成物 |
| WO2021021528A1 (en) * | 2019-07-26 | 2021-02-04 | Board Of Trustees Of Michigan State University | Methods of preventing or treating fatty degeneration of skeletal muscle |
| US20250270331A1 (en) * | 2019-12-24 | 2025-08-28 | Merus N.V. | Tgf-beta-rii binding proteins |
| KR102314157B1 (ko) * | 2020-01-10 | 2021-10-19 | 주식회사 뉴클릭스바이오 | TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법 |
| US20220144956A1 (en) * | 2020-11-06 | 2022-05-12 | Xencor, Inc. | HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII |
| IL305181A (en) | 2021-02-15 | 2023-10-01 | Takeda Pharmaceuticals Co | Cell therapy compositions and methods for modulating tgf-b signaling |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| JP2001206899A (ja) * | 1999-11-18 | 2001-07-31 | Japan Tobacco Inc | ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途 |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| CA2447851C (en) | 2001-06-28 | 2012-08-28 | Domantis Limited | Dual-specific ligand and its use |
| WO2003076567A2 (en) | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| EP3299393A1 (en) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| AU2003290330A1 (en) | 2002-12-27 | 2004-07-22 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| AU2004239065B2 (en) | 2003-05-14 | 2008-05-15 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
| AU2004220325B2 (en) | 2003-06-30 | 2011-05-12 | Domantis Limited | Polypeptides |
| EP1675878A2 (en) | 2003-10-24 | 2006-07-05 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| EP1729795B1 (en) | 2004-02-09 | 2016-02-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1737962B1 (en) | 2004-03-24 | 2010-09-01 | Domantis Limited | Gas1 universal leader |
| GB0418651D0 (en) | 2004-08-20 | 2004-09-22 | Medical Res Council | Method |
| US20070012251A1 (en) | 2005-07-07 | 2007-01-18 | Martin Zucker | Seal arrangement with corrosion barrier and method |
| CA2636854A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Ligands that bind il-4 and/or il-13 |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| JO3096B1 (ar) * | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| EA026097B1 (ru) * | 2009-07-29 | 2017-03-31 | Глаксо Груп Лимитед | Однодоменные антитела против рецептора tgf-бета ii типа |
| US20120316071A1 (en) * | 2009-11-04 | 2012-12-13 | Vaughn Smider | Methods for affinity maturation-based antibody optimization |
| CN103443126B (zh) * | 2011-01-06 | 2016-11-23 | 葛兰素集团有限公司 | 结合TGFβ受体II的配体 |
-
2012
- 2012-01-04 CN CN201280012010.6A patent/CN103443126B/zh not_active Expired - Fee Related
- 2012-01-04 US US13/978,228 patent/US9150651B2/en not_active Expired - Fee Related
- 2012-01-04 KR KR1020137020615A patent/KR101886898B1/ko not_active Expired - Fee Related
- 2012-01-04 CA CA2823104A patent/CA2823104A1/en not_active Abandoned
- 2012-01-04 JP JP2013547846A patent/JP6062375B2/ja not_active Expired - Fee Related
- 2012-01-04 MX MX2013007936A patent/MX2013007936A/es not_active Application Discontinuation
- 2012-01-04 ES ES12700019.8T patent/ES2627299T3/es active Active
- 2012-01-04 WO PCT/EP2012/050061 patent/WO2012093125A1/en not_active Ceased
- 2012-01-04 PH PH1/2013/501397A patent/PH12013501397A1/en unknown
- 2012-01-04 EP EP12700019.8A patent/EP2661449B1/en active Active
- 2012-01-04 BR BR112013016917A patent/BR112013016917A2/pt not_active Application Discontinuation
- 2012-01-04 SG SG2013049663A patent/SG191762A1/en unknown
- 2012-01-04 PE PE2013001516A patent/PE20140982A1/es not_active Application Discontinuation
- 2012-01-04 MA MA36101A patent/MA34820B1/fr unknown
- 2012-01-04 EA EA201391012A patent/EA201391012A1/ru unknown
-
2013
- 2013-06-25 ZA ZA2013/04726A patent/ZA201304726B/en unknown
- 2013-06-27 IL IL227254A patent/IL227254A0/en unknown
- 2013-07-03 DO DO2013000162A patent/DOP2013000162A/es unknown
- 2013-07-05 CL CL2013001975A patent/CL2013001975A1/es unknown
- 2013-07-16 CO CO13168686A patent/CO6811807A2/es unknown
- 2013-08-05 CR CR20130376A patent/CR20130376A/es unknown
-
2015
- 2015-09-02 US US14/843,250 patent/US9850307B2/en not_active Expired - Fee Related
-
2016
- 2016-05-31 AU AU2016203609A patent/AU2016203609A1/en not_active Abandoned
- 2016-10-20 JP JP2016205978A patent/JP6453289B2/ja not_active Expired - Fee Related
-
2017
- 2017-11-21 US US15/818,861 patent/US20180086835A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201391012A1 (ru) | Лиганды, связывающиеся с рецепторами tgf-бета типа ii | |
| HRP20210777T1 (hr) | Pripravci protiv cgrp-a njihova upotreba | |
| JP2014504866A5 (cg-RX-API-DMAC7.html) | ||
| EA201490809A1 (ru) | Способы и композиции для лечения неэффективного эритропоэза | |
| JP2012529436A5 (cg-RX-API-DMAC7.html) | ||
| EP2174668A3 (en) | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis | |
| RU2014111472A (ru) | Способ ингибирования клеточной активации, вызываемой инсулиноподобным фактором роста 1 | |
| EA201000018A1 (ru) | Лиофилизированные лекарственные формы иммуноглобулинов и способы их получения | |
| BR112015012366A2 (pt) | antagonistas de cxcr7 | |
| NZ591130A (en) | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof | |
| EA201201227A1 (ru) | Бипаратопные а-бета-связывающие полипептиды | |
| WO2006110214A3 (en) | Antibodies against mammalian metapneumovirus | |
| JP2012505912A5 (cg-RX-API-DMAC7.html) | ||
| EA201390739A1 (ru) | Способ лечения fgf21-ассоциированных расстройств | |
| RU2011110169A (ru) | Антитела против ccr2 | |
| UA104626C2 (ru) | Анти-vegf антитело и его применение | |
| RU2011141522A (ru) | Антиангиогенные слитые белки | |
| MX336391B (es) | Metodos y composiciones que usan polipeptidos de fusion de fgf23. | |
| EA201991704A2 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| JP2012511545A5 (cg-RX-API-DMAC7.html) | ||
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| EA201290028A1 (ru) | Однодоменные антитела против рецептора tgf-бета ii типа | |
| RU2013135175A (ru) | Фармацевтическая композиция комплекса антитела против дигоксигенина и дигоксигенина, конъюгированного с пептидом | |
| NZ599114A (en) | Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists | |
| WO2012009631A8 (en) | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods |